DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidates are oral antagonists of the pro-inflammatory signaling molecule, IL-17, which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting the integrin α4ß7 for the treatment of inflammatory bowel disease.
Company profile
Ticker
DICE
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
DiCE Molecules Holdings, LLC, DiCE MOLECULES HOLDINGS, LLC
SEC CIK
Corporate docs
Subsidiaries
DiCE Molecules SV, Inc. • DiCE Alpha, Inc. ...
IRS number
472286244
DICE stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
21 Aug 23
EFFECT
Notice of effectiveness
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 23
POSASR
Automatic shelf registration (post-effective amendment)
9 Aug 23
POS AM
Prospectus update (post-effective amendment)
9 Aug 23
8-K
Termination of a Material Definitive Agreement
9 Aug 23
SC 14D9/A
Tender offer solicitation (amended)
9 Aug 23
SC TO-T/A
Third party tender offer statement (amended)
9 Aug 23
Latest ownership filings
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 73.66 mm | 73.66 mm | 73.66 mm | 73.66 mm | 73.66 mm | 73.66 mm |
Cash burn (monthly) | 9.38 mm | (no burn) | 13.17 mm | 9.89 mm | 9.53 mm | 7.02 mm |
Cash used (since last report) | 92.18 mm | n/a | 129.43 mm | 97.24 mm | 93.65 mm | 69.00 mm |
Cash remaining | -18.52 mm | n/a | -55.77 mm | -23.58 mm | -19.98 mm | 4.66 mm |
Runway (months of cash) | -2.0 | n/a | -4.2 | -2.4 | -2.1 | 0.7 |
Institutional ownership, Q2 2023
92.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 162 |
Opened positions | 79 |
Closed positions | 33 |
Increased positions | 35 |
Reduced positions | 34 |
13F shares | Current |
---|---|
Total value | 1.98 tn |
Total shares | 44.04 mm |
Total puts | 895.30 k |
Total calls | 541.17 k |
Total put/call ratio | 1.7 |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 7.86 mm | $365.02 bn |
BLK Blackrock | 2.90 mm | $134.52 bn |
FMR | 2.24 mm | $104.03 bn |
Avoro Capital Advisors | 2.20 mm | $102.18 bn |
Alpine Associates Management | 2.12 mm | $98.35 bn |
Driehaus Capital Management | 2.04 mm | $94.70 bn |
Vanguard | 1.96 mm | $90.94 bn |
Magnetar Financial | 1.16 mm | $53.70 bn |
Pentwater Capital Management | 1.08 mm | $50.20 bn |
Baker Bros. Advisors | 1.04 mm | $48.12 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Aug 23 | Lisa Bowers | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 19.13 | 42,500 | 813.03 k | 0 |
9 Aug 23 | Mittie Doyle | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 19.13 | 42,500 | 813.03 k | 0 |
9 Aug 23 | John R. Jacobsen | Common Stock | Sale back to company | Dispose D | No | No | 0 | 147,497 | 0.00 | 0 |
9 Aug 23 | John R. Jacobsen | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 15,000 | 0.00 | 0 |
9 Aug 23 | John R. Jacobsen | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 32.31 | 90,000 | 2.91 mm | 0 |
9 Aug 23 | John R. Jacobsen | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 19.64 | 154,250 | 3.03 mm | 0 |
9 Aug 23 | John R. Jacobsen | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 17 | 46,324 | 787.51 k | 0 |
9 Aug 23 | John R. Jacobsen | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 17 | 11,064 | 188.09 k | 0 |
9 Aug 23 | John R. Jacobsen | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 17 | 7,579 | 128.84 k | 0 |
9 Aug 23 | John R. Jacobsen | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 17 | 14,341 | 243.80 k | 0 |